Breaking a vicious cycle

Science Translational Medicine

Volumn 5, Issue 196, 2013, Pages

  Hayes, Daniel F ^a   Allen, Jef ^b   Compton, Carolyn ^c   Gustavsen, Gary ^d   Leonard, Debra G B ^e   McCormack, Robert ^f   Newcomer, Lee ^g   Pothier, Kristin ^d   Ransohoff, David ^h   Schilsky, Richard L ⁱ   Sigal, Ellen ^b   Taube, Sheila E ^j   Tunis, Sean R ^k  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Friends of Cancer Research   (United States)

^c CRITICAL PATH INSTITUTE   (United States)

^d Health Advances   (United States)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^f Veridex LLC   (United States)

^g United Health Group   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^j ST Consulting   (United States)

^k Center for Medical Technology Policy   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER RESEARCH; CANCER THERAPY; DIAGNOSTIC TEST; FOOD AND DRUG ADMINISTRATION; HUMAN; INVESTMENT; LAW; PATIENT CARE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REIMBURSEMENT; RELIABILITY; STANDARD; VALIDITY;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; NEOPLASMS; PEER REVIEW, RESEARCH; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883882396     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005950     Document Type: Article

References (32)

1. S. N. Khleif, J. H. Doroshow, W. N. Hait, AACR-FDA-NCI Cancer Biomarkers Collaborative, AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: Advancing the use of biomarkers in cancer drug development. Clin. Cancer Res. 16, 3299-3318 (2010).
2. G. Sölétormos, M. J. Duffy, D. F. Hayes, C. M. Sturgeon, V. Barak, P. M. Bossuyt, E. P. Diamandis, M. Gion, P. Hyltoft-Petersen, R. M. Lamerz, D. L. Nielsen, P. Sibley, B. Tholander, M. K. Tuxen, J. M. Bonfrer, Design of tumor biomarker-monitoring trials: A proposal by the European Group on Tumor Markers. Clin. Chem. 59, 52-59 (2013).
3. L. Wang, H. L. McLeod, R. M. Weinshilboum, Genomics and drug response. N. Engl. J. Med. 364, 1144-1153 (2011).
4. S. M. Teutsch, L. A. Bradley, G. E. Palomaki, J. E. Haddow, M. Piper, N. Calonge, W. D. Dotson, M. P. Douglas, A. O. Berg, EGAPP Working Group, The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: Methods of the EGAPP Working Group. Genet. Med. 11, 3-14 (2009).
5. D. F. Hayes, R. C. Bast, C. E. Desch, H. Fritsche Jr., N. E. Kemeny, J. M. Jessup, G. Y. Locker, J. S. Macdonald, R. G. Mennel, L. Norton, P. Ravdin, S. Taube, R. J. Winn, Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. 88, 1456-1466 (1996).
6. R. M. Simon, S. Paik, D. F. Hayes, Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst. 101, 1446-1452 (2009).
7. Institute of Medicine, Evolution of Translational Omics: Lessons Learned and the Path Forward, C. Micheel, S. Nass, G. S. Omenn, Eds. (National Academies Press, Washington, DC, 2012).
8. G. Gustavsen, K. Phillips, K. Pothier, "The reimbursement landscape for novel diagnostics: Current limitations, real world impact and proposed solutions" (Weston, MA, 2010).
9. L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, R. C. Bast Jr., American Society of Clinical Oncology, American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25, 5287-5312 (2007).
10. P. G. Febbo, M. Ladanyi, K. D. Aldape, A. M. De Marzo, M. E. Hammond, D. F. Hayes, A. J. Iafrate, R. K. Kelley, G. Marcucci, S. Ogino, W. Pao, D. C. Sgroi, M. L. Birkeland, NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J. Natl. Compr. Canc. Netw. 9, S1-S32, quiz S33 (2011).
11. M. Mitka, Group now advises against routine PSA screening. J. Am. Med. Assoc. 309, 2316 (2013).
12. S. Olson, A. C. Berger, in IOM Roundtable on Translating Genomic-Based Research for Health Board on Health Sciences Policy (National Academies Press, Washington, DC, 2011).
13. W. B. Mattes, E. G. Walker, E. Abadie, F. D. Sistare, J. Vonderscher, J. Woodcock, R. L. Woosley, Research at the interface of industry, academia and regulatory science. Nat. Biotechnol. 28, 432-433 (2010).
14. M. Angell, Excess in the pharmaceutical industry. CMAJ 171, 1451-1453 (2004).
15. M. Angell, The pharmaceutical industry-To whom is it accountable? N. Engl. J. Med. 342, 1902-1904 (2000).
16. S. Rosen, "The World Market for Molecular Diagnostics" (Kalorama Information, New York, 2013).
17. G. H. Lyman, L. E. Cosler, N. M. Kuderer, J. Hornberger, Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies. Cancer 109, 1011-1018 (2007).
18. C. J. Allegra, J. M. Jessup, M. R. Somerfield, S. R. Hamilton, E. H. Hammond, D. F. Hayes, P. K. McAllister, R. F. Morton, R. L. Schilsky, American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096 (2009).
19. D. J. Sargent, B. A. Conley, C. Allegra, L. Collette, Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 23, 2020-2027 (2005).
20. B. Freidlin, L. M. McShane, E. L. Korn, Randomized clinical trials with biomarkers: Design issues. J. Natl. Cancer Inst. 102, 152-160 (2010).
21. J. A. Sparano, S. Paik, Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26, 721-728 (2008).
22. D. F. Hayes, J. Smerage, Is there a role for circulating tumor cells in the management of breast cancer? Clin. Cancer Res. 14, 3646-3650 (2008).
23. D. F. Hayes, Targeting adjuvant chemotherapy: A good idea that needs to be proven! J. Clin. Oncol. 30, 1264-1267 (2012).
24. S. Nass, H. Moses, J. Mendelsohn, A National Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program (The National Academies Press, Washington, DC, 2010).
25. K. F. Schulz, D. G. Altman, D. Moher, CONSORT Group, CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Ann. Intern. Med. 152, 726-732 (2010).
26. L. M. McShane, D. F. Hayes, Publication of tumor marker research results: The necessity for complete and transparent reporting. J. Clin. Oncol. 30, 4223-4232 (2012).
27. H. M. Moore, A. B. Kelly, S. D. Jewell, L. M. McShane, D. P. Clark, R. Greenspan, D. F. Hayes, P. Hainaut, P. Kim, E. Mansfield, O. Potapova, P. Riegman, Y. Rubinstein, E. Seijo, S. Somiari, P. Watson, H. U. Weier, C. Zhu, J. Vaught, Biospecimen reporting for improved study quality (BRISQ). J. Proteome Res. 10, 3429-3438 (2011).
28. H. M. Moore, A. B. Kelly, S. D. Jewell, L. M. McShane, D. P. Clark, R. Greenspan, D. F. Hayes, P. Hainaut, P. Kim, E. A. Mansfield, O. Potapova, P. Riegman, Y. Rubinstein, E. Seijo, S. Somiari, P. Watson, H. U. Weier, C. Zhu, J. Vaught, Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 119, 92-102 (2011).
29. F. Andre, L. M. McShane, S. Michiels, D. F. Ransohoff, D. G. Altman, J. S. Reis-Filho, D. F. Hayes, L. Pusztai, Biomarker studies: A call for a comprehensive biomarker study registry. Nat Rev Clin Oncol 8, 171-176 (2011).
30. S. Mallett, A. Timmer, W. Sauerbrei, D. G. Altman, Reporting of prognostic studies of tumour markers: A review of published articles in relation to REMARK guidelines. Br. J. Cancer 102, 173 (2010).
31. N. L. Henry, D. F. Hayes, Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 11, 541-552 (2006).
32. D. F. Hayes, J. Allen, C. Compton, G. Gustavsen, D. G. B. Leonard, R. McCormack, L. Newcomer, K. Pothier, D. Ransohoff, R. L. Schilsky, E. Sigal, S. E. Taube, S. R. Tunis, Breaking a vicious cycle. Sci. Transl. Med. 5, 196cm6 (2013).